Literature DB >> 10781700

Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS).

C Lançon1, P Auquier, G Reine, D Bernard, M Toumi.   

Abstract

The aim of this study was to investigate the concurrent validity of the French language version of the Calgary Depression Scale for Schizophrenics (CDSS). Ninety-five schizophrenic patients meeting the DSM-III-R criteria were enrolled in the study. The depressive symptoms were evaluated using the Calgary Depression Scale for Schizophrenics (CDSS), Hamilton Depression Rating Scale (HDRS), Montgomery and Asberg Rating Scale (MADRS), and Widlocher Psychomotor Retardation Scale (ERD). The psychotic symptoms were evaluated with the Positive and Negative Syndrome Scale (PANSS) and the extrapyramidal symptoms with the Extrapyramidal Syndrome Rating Scale (ESRS). The CDDS was significantly correlated with all the conventional depression-rating scales. We only found significant positive correlations between the CDSS and the PANSS-positive sub-scale. The CDSS total score was significantly correlated with some PANSS-positive items (delusions and hallucinatory behaviour). No significant correlation between the depression-rating scales and the PANSS-negative sub-scale was observed. For all the depression-rating scales, no correlation with the extrapyramidal symptom was evidenced. The results confirmed the validity of the CDSS in the evaluation of depression in schizophrenia. The relationship between depression and the positive symptoms of schizophrenia is discussed.

Entities:  

Mesh:

Year:  2000        PMID: 10781700     DOI: 10.1016/s0165-0327(99)00075-0

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  7 in total

1.  Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms.

Authors:  Sonia Dollfus; Cyril Mach; Rémy Morello
Journal:  Schizophr Bull       Date:  2015-11-12       Impact factor: 9.306

2.  Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial.

Authors:  Leandro da Costa Lane Valiengo; Stephan Goerigk; Pedro Caldana Gordon; Frank Padberg; Mauricio Henriques Serpa; Stephanie Koebe; Leonardo Afonso Dos Santos; Roger Alberto Marcos Lovera; Juliana Barbosa de Carvalho; Martinus van de Bilt; Acioly L T Lacerda; Helio Elkis; Wagner Farid Gattaz; Andre R Brunoni
Journal:  JAMA Psychiatry       Date:  2020-02-01       Impact factor: 21.596

3.  Comorbid Moderate-Severe Depressive Symptoms and their Association with Quality of Life in Chinese Patients with Schizophrenia Treated in Primary Care.

Authors:  Cai-Lan Hou; Xin-Rong Ma; Mei-Ying Cai; Yan Li; Yu Zang; Fu-Jun Jia; Yong-Qiang Lin; Helen F K Chiu; Gabor S Ungvari; Brian J Hall; Bao-Liang Zhong; Xiao-Lan Cao; Yu-Tao Xiang
Journal:  Community Ment Health J       Date:  2016-06-15

4.  Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis.

Authors:  Jean Addington; Hely Shah; Lu Liu; Donald Addington
Journal:  Schizophr Res       Date:  2014-01-16       Impact factor: 4.939

5.  Depression: An actionable outcome for those at clinical high-risk.

Authors:  Jean Addington; Megan S Farris; Lu Liu; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Carrie E Bearden; Daniel H Mathalon; William S Stone; Matcheri Keshevan; Scott W Woods
Journal:  Schizophr Res       Date:  2020-10-29       Impact factor: 4.939

6.  Reliability and validity of the Thai version of the Calgary Depression Scale for Schizophrenia.

Authors:  Sirijit Suttajit; Manit Srisurapanont; Sutrak Pilakanta; Chawanun Charnsil; Siritree Suttajit
Journal:  Neuropsychiatr Dis Treat       Date:  2013-01-16       Impact factor: 2.570

7.  The latent structure of depressive symptoms across clinical high risk and chronic phases of psychotic illness.

Authors:  Teresa Vargas; Anthony O Ahmed; Gregory P Strauss; Cassandra M Brandes; Elaine F Walker; Robert W Buchanan; James M Gold; Vijay A Mittal
Journal:  Transl Psychiatry       Date:  2019-09-16       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.